怀柔医药科技企业拟北交所上市，思睦瑞科获北京医药基金参股

Company Overview - Beijing Simu Ruike Pharmaceutical Technology Co., Ltd. was established on May 9, 2008, with a registered capital of 63.84 million yuan [1] - The company is located in the Yanqi Economic Development Zone, Huairou District, Beijing [1] - The controlling shareholder is Beijing Simu Wansheng Management Consulting Co., Ltd., holding 18.58% of the shares [1] IPO and Market Activity - The company completed its IPO counseling record at the Beijing Securities Regulatory Bureau on September 2, 2023, and plans to list on the Beijing Stock Exchange [1] - Simu Ruike submitted its initial public offering application to the Shenzhen Stock Exchange in June 2022 but withdrew the application in December 2023 [1] Shareholding Structure - The major shareholders include: - Simu Wansheng: 11,862,620 shares (18.58%) - Wei Pengpai: 8,045,400 shares (12.60%) - Bai Ao Sai Si: 7,700,000 shares (12.06%) - Other shareholders hold varying percentages, totaling 82.23% among the top shareholders [2] Financial Performance - For the fiscal years 2023 and 2024, the company reported revenues of 445.93 million yuan and 417.61 million yuan, respectively [3] - The net profit for the same years was 95.12 million yuan in 2023 and 101.66 million yuan in 2024, indicating a profit increase despite a revenue decline [3] - The comprehensive gross profit margin improved from 37.50% in 2023 to 43.00% in 2024 [3] Business Segment Insights - The decline in revenue is attributed to reduced income from public health event-related services [4] - Excluding the impact of public health event revenues, the income from clinical trial operation services showed a growth trend, with figures of 247.00 million yuan and 281.28 million yuan for the respective years [4]